Evaluation of the tablet core factors influencing the release kinetics and the loadability of push-pull osmotic systems

Drug Development and Industrial Pharmacy

Volumn 35, Issue 4, 2009, Pages 433-439

  Malaterre, Vincent ^a   Ogorka, Joerg ^b   Loggia, Nicoletta ^a   Gurny, Robert ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

Extended release

Indexed keywords

ISRADIPINE; OSMOTIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; EXCIPIENT; MACROGOL DERIVATIVE;

ARTICLE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; MOLECULAR WEIGHT; PUSH PULL OSMOTIC SYSTEM; TABLET FORMULATION; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG STABILITY; EQUIPMENT DESIGN; HYDROGEL; KINETICS; METHODOLOGY; OSMOTIC PRESSURE; PH; PHARMACEUTICS; SOLUBILITY; TABLET;

CALCIUM CHANNEL BLOCKERS; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; DRUG STABILITY; EQUIPMENT DESIGN; EXCIPIENTS; HYDROGEL; HYDROGEN-ION CONCENTRATION; ISRADIPINE; KINETICS; OSMOTIC PRESSURE; POLYETHYLENE GLYCOLS; SOLUBILITY; TABLETS; TECHNOLOGY, PHARMACEUTICAL;

EID: 65749098490     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.1080/03639040802425230     Document Type: Article

References (23)

1. Abrahamsson, B., Alpsten, M., Bake, B., Jonsson, U. E., Eriksson-Lepkowska, M., & Larsson, A. (1998). Drug absorption from nifedipine hydrophilic matrix extended-release (ER) tablet-comparison with an osmotic pump tablet and effect of food. J. Control. Release, 52, 301-310.
2. Ayer, A., & Ridzon, D. (1993). Tandospirone antidepressant therapy. U.S. Patent No. 5,330,762. January 27.
3. Bartlett, M. G., Spell, J. C., Mathis, P. S., Elgany, M. F. A., El Zeany, B. E., Elkawy, M. A., & Stewart, J. T. (1998). Determination of degradation products from the calcium-channel blocker isradipine. J. Pharm. Biom. Anal., 18, 335-345.
4. Bass, D. M., Prevo, M., & Waxman, D. S. (2002). Gastrointestinal safety of an extended-release, nondeformable, oral dosage form (OROS (R))(1)-a retrospective study. Drug Saf., 25, 1021-1033.
5. Fitton, A., & Benfield, P. (1990). Isradipine-a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease. Drugs, 40, 31-74.
6. Jamzad, S., & Fassihi, R. (2006). Development of a controlled release low dose class II drug-Glipizide. Int. J. Pharm., 312, 24-32.
7. Liu, L., & Xu, X. (2008). Preparation of bilayer-core osmotic pump tablet by coating the indented core tablet. Int. J. Pharm., 352, 225-230.
8. Liu, L. X., Ku, J., Khang, G., Lee, B., Rhee, J. M., & Lee, H. B. (2000). Nifedipine controlled delivery by sandwiched osmotic tablet system. J. Control. Release, 68, 145-156. (Pubitemid 30488892)
9. Nokhodchi, A., Momin, M. N., Shokri, J., Shahsavari, M., & Rashidi, P. A. (2008). Factors affecting the release of nifedipine from a swellable elementary osmotic pump. Drug Deliv., 15, 43-48.
10. Pillay, V., & Fassihi, R. (1998). Evaluation and comparison of dissolution data derived from different modified release dosage forms: An alternative method. J. Control. Release, 55, 45-55.
11. Prisant, L. M., & Elliott, W. J. (2003). Drug delivery systems for treatment of systemic hypertension. Clin. Pharmacokinet., 42, 931-940.
12. Schug, B. S., Brendel, E., Chantraine, E., Wolf, D., Martin, W., Schall, R., & Blume, H. H. (2002a). The effect of food on the pharmacokinetics of nifedipine in two slow release formulations: Pronounced lag-time after a high fat breakfast. Brit. J. Clin. Pharm., 53, 582-588.
13. Schug, B. S., Brendel, E., Wolf, D., Wonnemann, M., Wargenau, M., & Blume, H. H. (2002b). Formulation-dependent food effects demonstrated for nifedipine modified-release preparations marketed in the European Union. Eur. J. Pharm. Sci., 15, 279-285.
14. Shah, V. P., Tsong, Y., Sathe, P., & Liu, J. P. (1998). In vitro dissolution profile comparison-statistics and analysis of the similarity factor, f(2). Pharm. Res., 15, 889-896.
15. Shokri, J., Ahmadi, P., Rashidi, P., Shahsavari, M., Rajabi-Siahboomi, A., & Nokhodchi, A. (2008). Swellable elementary osmotic pump (SEOP): An effective device for delivery of poorly water-soluble drugs. Eur. J. Pharm. Biopharm., 68, 289-297.
16. Thombre, A. G., Appel, L. E., Chidlaw, M. B., Daugherity, P. D., Dumont, F., Evans, L. A. F., & Sutton, S. C. (2004). Osmotic drug delivery using swellable-core technology. J. Control. Release, 94, 75-89.
17. US Pharmacopeia XXX (2006). Section 711 and Isradipine monograph. United State Pharmacopeial Convention, Rockville, MD, pp. 1941-1943, 2482.
18. Verma, R. K., Viswanathan, N. B., Raghuvanshi, R. A., & Pampal, A. (2006). Osmotic dosage forms providing ascending drug release, and processes for their preparation. W.O. Patent No. 2006/046114, May 4.
19. Wong, P., Donn, K. H., Zhao, R., & Pollock-Dove, C. (2006). Controlled release nanoparticle active agent formulation dosage forms and methods. W.O. Patent No. 2006/023286, March 2.
20. Wonnemann, M., Schug, B., Schmucker, K., Brendel, E., van Zwieten, P. A., & Blumel, H. (2006). Significant food interactions observed with a nifedipine modified-release formulation marketed in the European Union. Int. J. Clin. Pharm. Ther., 44, 38-48.
21. Wu, N., Wang, L. S., Tan, D. C. W., Moochhala, S. M., & Yang, Y. Y. (2005). Mathematical modeling and in vitro study of controlled drug release via a highly swellable and dissoluble polymer matrix: Polyethylene oxide with high molecular weights. J. Control. Release, 102, 569-581.
22. Yang, L. B., Venkatesh, G., & Fassihi, R. (1996). Characterization of compressibility and compactibility of poly(ethylene oxide) polymers for modified release application by compaction simulator. J. Pharm. Sci., 85, 1085-1090.
23. Yu, D. M., Amidon, G. L., Weiner, N. D., & Goldberg, A. H. (1994). Viscoelastic properties of poly(ethylene oxide) solution. J. Pharm. Sci., 83, 1443-1449.